» Articles » PMID: 38962013

Identifying and Evaluating a Disulfidptosis-related Gene Signature to Predict Prognosis in Colorectal Adenocarcinoma Patients

Overview
Journal Front Immunol
Date 2024 Jul 4
PMID 38962013
Authors
Affiliations
Soon will be listed here.
Abstract

Disulfidptosis, a regulated form of cell death, has been recently reported in cancers characterized by high SLC7A11 expression, including invasive breast carcinoma, lung adenocarcinoma, and hepatocellular carcinoma. However, its role in colon adenocarcinoma (COAD) has been infrequently discussed. In this study, we developed and validated a prognostic model based on 20 disulfidptosis-related genes (DRGs) using LASSO and Cox regression analyses. The robustness and practicality of this model were assessed via a nomogram. Subsequent correlation and enrichment analysis revealed a relationship between the risk score, several critical cancer-related biological processes, immune cell infiltration, and the expression of oncogenes and cell senescence-related genes. POU4F1, a significant component of our model, might function as an oncogene due to its upregulation in COAD tumors and its positive correlation with oncogene expression. assays demonstrated that POU4F1 knockdown noticeably decreased cell proliferation and migration but increased cell senescence in COAD cells. We further investigated the regulatory role of the DRG in disulfidptosis by culturing cells in a glucose-deprived medium. In summary, our research revealed and confirmed a DRG-based risk prediction model for COAD patients and verified the role of POU4F1 in promoting cell proliferation, migration, and disulfidptosis.

Citing Articles

Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors.

Du F, Wang G, Dai Q, Huang J, Li J, Liu C Biomark Res. 2025; 13(1):35.

PMID: 40012016 PMC: 11866848. DOI: 10.1186/s40364-025-00748-4.


Advances in the study of disulfidptosis in digestive tract tumors.

Chen Y, Zhang D, Yang H, Wu J, He W Discov Oncol. 2025; 16(1):186.

PMID: 39954025 PMC: 11829889. DOI: 10.1007/s12672-025-01875-y.


Exploring prognosis and therapeutic strategies for HBV-HCC patients based on disulfidptosis-related genes.

Zhang C, Zhang X, Dai S, Yang W Front Genet. 2025; 15:1522484.

PMID: 39882072 PMC: 11774838. DOI: 10.3389/fgene.2024.1522484.


A novel liquid-liquid phase separation-related gene signature for predicting prognosis in colon cancer.

Wang S, Hou S, Jiang S, Wang C, Zhang P, Ye Y Front Immunol. 2025; 15:1514613.

PMID: 39749343 PMC: 11693697. DOI: 10.3389/fimmu.2024.1514613.

References
1.
Yang L, Liu J, Li S, Liu X, Zheng F, Xu S . Based on disulfidptosis, revealing the prognostic and immunological characteristics of renal cell carcinoma with tumor thrombus of vena cava and identifying potential therapeutic target AJAP1. J Cancer Res Clin Oncol. 2023; 149(12):9787-9804. DOI: 10.1007/s00432-023-04877-x. View

2.
Lui R, Tsoi K, Ho J, Lo C, Chan F, Kyaw M . Global Increasing Incidence of Young-Onset Colorectal Cancer Across 5 Continents: A Joinpoint Regression Analysis of 1,922,167 Cases. Cancer Epidemiol Biomarkers Prev. 2019; 28(8):1275-1282. DOI: 10.1158/1055-9965.EPI-18-1111. View

3.
Maeser D, Gruener R, Huang R . oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021; 22(6). PMC: 8574972. DOI: 10.1093/bib/bbab260. View

4.
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

5.
Fiori M, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R . Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019; 18(1):70. PMC: 6441236. DOI: 10.1186/s12943-019-0994-2. View